Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 12:03 save search
Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections
Published: 2021-03-06 (Crawled : 12:03) - globenewswire.com
AVIR | $3.705 -0.67% -0.67% 200K
|
Health Technology
| Email alert
Add to watchlist
phase 1 results phase 3 phase 2 injection at-527 infections
Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases
Published: 2021-03-02 (Crawled : 12:03) - globenewswire.com
KYMR | $35.18 -1.48% -1.51% 380K
|
Health Technology
|
| O: 0.0%
H: 3.09%
C: -3.3%
disease phase 1 trial phase 3 phase 2
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.73 -3.55% -3.68% 330K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Published: 2021-02-22 (Crawled : 12:03) - globenewswire.com
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -3.56%
H: 3.41%
C: -8.55%
covid vaccine phase 3 trial enroll
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
Published: 2021-02-22 (Crawled : 12:03) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: -49.54%
H: 23.53%
C: 10.29%
disease results phase 3 trial topline
Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate
Published: 2021-02-09 (Crawled : 12:03) - globenewswire.com
HROW P | $10.275 -0.44% -0.44% 410K
|
Health Technology
|
| O: -1.54%
H: 1.75%
C: -3.68%
drug phase 1 opioid phase 3 phase 2
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Published: 2021-02-02 (Crawled : 12:03) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 18.82%
H: 7.61%
C: -6.37%
sclerosis phase 3 ongoing
Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
Published: 2021-01-19 (Crawled : 12:03) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 2.73%
H: 2.65%
C: -0.88%
results biotech phase 3
Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis
Published: 2021-01-14 (Crawled : 12:03) - globenewswire.com
ORGO | $2.99 0.34% 0.33% 2.5M
|
Finance
|
| O: 32.7%
H: 7.9%
C: -2.57%
phase 3 trial osteoarthritis enroll designation rmat
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Published: 2021-01-06 (Crawled : 12:03) - globenewswire.com
OCUP | News | $1.52 -1.3% -1.32% 90K
|
Health Technology
|
| O: 0.0%
H: 1.32%
C: -4.64%
phase 3 trial enroll
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Published: 2021-01-05 (Crawled : 12:03) - globenewswire.com
OCUP | News | $1.52 -1.3% -1.32% 90K
|
Health Technology
|
| O: 1.57%
H: 7.59%
C: 6.19%
phase 3 pharma
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
Published: 2020-12-22 (Crawled : 12:03) - globenewswire.com
RYTM 4 | $39.71 -0.73% -0.73% 400K
|
Health Technology
|
| O: -5.08%
H: 1.68%
C: 0.54%
results phase 3 positive trial topline setmelanotide syndros
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: -6.0%
H: 5.73%
C: 2.17%
results phase 3 topline
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.